Hemophilia A - Pipeline Review, H1 2018

May 2018 | 182 pages | ID: HFA77C65968EN
Global Markets Direct

Abstracts

Hemophilia A - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 4, 24, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hemophilia A - Overview
Hemophilia A - Therapeutics Development
Hemophilia A - Therapeutics Assessment
Hemophilia A - Companies Involved in Therapeutics Development
Hemophilia A - Drug Profiles
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hemophilia A, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2018
Hemophilia A - Pipeline by Apitope International NV, H1 2018
Hemophilia A - Pipeline by Bayer AG, H1 2018
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2018
Hemophilia A - Pipeline by Bioverativ Inc, H1 2018
Hemophilia A - Pipeline by Casebia Therapeutics, H1 2018
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2018
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Hemophilia A - Pipeline by CSL Ltd, H1 2018
Hemophilia A - Pipeline by DBV Technologies SA, H1 2018
Hemophilia A - Pipeline by EpiVax Inc, H1 2018
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2018
Hemophilia A - Pipeline by GC Pharma, H1 2018
Hemophilia A - Pipeline by ID Pharma Co Ltd, H1 2018
Hemophilia A - Pipeline by Idogen AB, H1 2018
Hemophilia A - Pipeline by Immusoft Corp, H1 2018
Hemophilia A - Pipeline by Innovare R & D SA De CV, H1 2018
Hemophilia A - Pipeline by LFB SA, H1 2018
Hemophilia A - Pipeline by mAbxience SA, H1 2018
Hemophilia A - Pipeline by Novo Nordisk AS, H1 2018
Hemophilia A - Pipeline by Okklo Life Sciences BV, H1 2018
Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2018
Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2018
Hemophilia A - Pipeline by Pfizer Inc, H1 2018
Hemophilia A - Pipeline by Pharming Group NV, H1 2018
Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2018
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2018
Hemophilia A - Pipeline by Shire Plc, H1 2018
Hemophilia A - Pipeline by Sino Biopharmaceutical Ltd, H1 2018
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2018
Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2018
Hemophilia A - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018
Hemophilia A - Pipeline by UniQure NV, H1 2018
Hemophilia A - Pipeline by XL-protein GmbH, H1 2018
Hemophilia A - Dormant Projects, H1 2018
Hemophilia A - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hemophilia A, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

Alnylam Pharmaceuticals Inc
Amarna Therapeutics BV
Apitope International NV
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Casebia Therapeutics
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
EpiVax Inc
Expression Therapeutics LLC
GC Pharma
ID Pharma Co Ltd
Idogen AB
Immusoft Corp
Innovare R & D SA De CV
LFB SA
mAbxience SA
Novo Nordisk AS
Okklo Life Sciences BV
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
Sangamo Therapeutics Inc
Shire Plc
Sino Biopharmaceutical Ltd
SK Chemicals Co Ltd
Spark Therapeutics Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
XL-protein GmbH